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Abstract Nitrates have been used to treat symptoms of
chronic stable angina for over 135 years. These drugs are
known to activate nitric oxide (NO)-cyclic guanosine-3′,-5′-
monophasphate (cGMP) signaling pathways underlying vas-
cular smooth muscle cell relaxation, albeit many questions
relating to how nitrates work at the cellular level remain un-
answered. Physiologically, the anti-angina effects of nitrates
are mostly due to peripheral venous dilatation leading to re-
duction in preload and therefore left ventricular wall stress,
and, to a lesser extent, epicardial coronary artery dilatation
and lowering of systemic blood pressure. By counteracting
ischemic mechanisms, short-acting nitrates offer rapid relief
following an angina attack. Long-acting nitrates, used com-
monly for angina prophylaxis are recommended second-line,
after beta-blockers and calcium channel antagonists.
Nicorandil is a balanced vasodilator that acts as both NO do-
nor and arterial K+ATP channel opener. Nicorandil might also
exhibit cardioprotective properties via mitochondrial ischemic
preconditioning. While nitrates and nicorandil are effective
pharmacological agents for prevention of angina symptoms,
when prescribing these drugs it is important to consider that
unwanted and poorly tolerated hemodynamic side-effects
such as headache and orthostatic hypotension can often occur
owing to systemic vasodilatation. It is also necessary to ensure
that a dosing regime is followed that avoids nitrate tolerance,
which not only results in loss of drug efficacy, but might also
cause endothelial dysfunction and increase long-term cardio-
vascular risk. Here we provide an update on the pharmacolog-
ical management of chronic stable angina using nitrates and
nicorandil.
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Introduction
Nitroglycerine was first applied to treat stable angina in 1876,
[1] and its clinical usefulness continues to this day; indeed
short-acting sublingual glyceryl trinitrate (GTN) is currently
recommended for all patients as the best first-line treatment for
relief of acute angina symptoms [2, 3]. Long-acting nitrates,
including isosorbide mononitrate (ISMN) and dinitrate
(ISDN), are important second-line preventative drugs.
Nitrate vasodilators are metabolized to nitric oxide (NO) with-
in vascular smooth muscle cells, resulting in dilatation of sys-
temic and coronary vascular beds [4]. While decades of re-
search relating to NO signaling pathways have revealed some
of the greatest discoveries in vascular biology and physiology,
including seminal work by three Nobel prize laureates, [5–7]
still, precise mechanisms underlying nitrate biotransforma-
tion, mode of action, and the molecular basis of nitrate toler-
ance remain incompletely understood [8]. Nitrates are often
regarded as ‘neutral’ in regards to cardiovascular risk– how-
ever new insights suggest a combination of potentially bene-
ficial and/or deleterious effects linked to long-term use [9].
Nicorandil is another vasodilator commonly used to treat
chronic stable angina, although it is not currently available in
the United States. Unlike nitrates, the actions of nicorandil
result in ‘balanced’ arterial and venous dilatation, mediated
via two distinct anti-angina mechanisms [10]. In addition,
* Juan Carlos Kaski
jkaski@sgul.ac.uk
1 Division of Cardiovascular Medicine, University of Cambridge,
Box 110, ACCI, Addenbrooke’s Hospital, Cambridge CB2 QQ, UK
2 Cardiovascular and Cell Sciences Research Institute, St George’s,
University of London, Cranmer Terrace, Tooting, London SW17
0RE, UK
Cardiovasc Drugs Ther
DOI 10.1007/s10557-016-6668-z
nicorandil is not associated with tolerance or rebound
angina, and there is some (albeit inconclusive) evidence
to suggest prognostic benefit due to reduction in oxida-
tive stress during myocardial ischemic reperfusion injury
[11].
Successful pharmacological management of stable angina
hinges on appropriate drug selection, tailored to individual
patient needs [12]. Nitrates and nicorandil are effective
second-line drugs for prophylaxis of effort-induced angina,
[13] as well as angina due to coronary spasm, ‘mixed’ angina,
and for some patients with microvascular dysfunction
[14–16]. Knowledge of specific pharmaco-therapeutic actions
and tolerability profiles of these drugs can provide foresight to
help optimize medical therapy and reduce frequency of un-
wanted side effects.
Nitrates
Nitrate vasodilators comprise a group of organic nitrate esters
with a nitrooxy (−O-NO2) moiety, which can be used as
mono- or add-on therapy in combination with other anti-
angina drugs [17, 18]. GTN, ISMN, and ISDN are the most
frequently prescribed nitrates. Pentaerythrityl tetranitrate
(PETN) is a high-potency long-acting nitrate, which is not
currently recommended due to lack of clinical efficacy data
[19].
Mechanism of Action
The molecular basis of nitrate pharmacotherapy is mediated
via activation of endogenous NO-cGMP signaling pathways
[20]. Nitrates act as NO donors, [21, 22] possibly compensat-
ing for compromised endothelial function in patients with cor-
onary atherosclerosis [23–25]. NO is widely accepted as the
effector compound responsible for nitrate-induced vascular
smooth muscle cell relaxation, [26] although several studies
have reported discrepancy between nitrate vasoactivity and
degree of NO release [27, 28].
While several mechanisms of nitrate bioactivation have yet
to be fully elucidated, it is known that GTN and PETN are
prodrugs, metabolized at therapeutic concentrations by mito-
chondrial aldehyde-dehydrogenase (ALDH-2) [29]. GTN is
converted by ALDH-2 to its denitrated metabolite (1,2-
gylceryl dinitrate) and nitrite (NO2); in theory, NO is then
generated from either NO2 reduction, or as direct result of
interaction between the two metabolites [30]. Presence of an
ALDH-2 polymorphism resulting in Glu504Lys substitution,
which eliminates ALDH2 activity, has been associated with
lack of response to sublingual GTN in a Chinese patient pop-
ulation [31]. ISDN and ISMN bioactivation is independent of
ALDH-2 activity, and in part due to cytochromal p450 metab-
olism in the endoplasmic reticulum, but this process is less
well understood [32, 33]. After bioactivation, nitrate-
generated NO activates soluble guanylate cyclase, increasing
cGMP production and activation of cGMP-dependent
kinases/ cyclic nucleotide-gated ion channels [34, 35].
Ultimately, this causes vasorelaxation due to reduction in in-
tracellular free Ca2+ and desensitization of smooth muscle cell
contractile elements to Ca2+ [36].
Hemodynamic Effects
The hemodynamic effects of nitrates help to alleviate angina
symptoms by reducing myocardial oxygen demand and
improving myocardial blood flow (Fig. 1). At therapeu-
tic doses, nitrates affect venous capacitance vessels pre-
dominately, but also dilate large and medium sized cor-
onary arteries, and arterioles >100μm [37–39]. Peripheral
venous dilatation results in venous pooling and thus
decreased venous return, thereby lowering left ventricu-
lar end-diastolic filling pressure (preload) and volume,
decreasing myocardial work and oxygen demands, and
indirectly increasing sub-endocardial blood flow. At
higher doses, nitrates result in arterial vasodilatation,
reducing systemic vascular resistance (afterload) and
blood pressure.
Myocardial blood flow is improved by dilatation of epicar-
dial and collateral coronary arteries, particularly stenotic
arterial segments prone to spasm [40–43]. GTN dilates
normal coronary arteries by 18 %, and lowers coronary
resistance by 38 % in arteries with severe stenosis [44].
The net hemodynamic effect of GTN on the coronary
circulation replenishes myocardial blood flow to ische-
mic regions [45–47]. Overall, nitrates do not significantly
alter cardiac output when used for chronic stable angina, and
have limited effect on blood pressure at usual non-parental
doses. However, as venous pooling is greatest in the upright
position, this can increase the risk of orthostatic hypotension
in patients taking nitrates [48].
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Fig. 1 Anti-angina actions of nitrates and nicorandil
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Non-Hemodynamic Effects and Cardiovascular Risk
Despite its long track record, consequences of chronic nitrate
use remain uncertain. Nitrates have important actions beyond
their role as vasorelaxants; some of these actions might be
cardioprotective, whereas others have been linked to increased
cardiac risk [9]. Firstly, nitrates inhibit platelet adherence and
activation [49]. Increased platelet cGMP decreases fibrinogen
binding to the glycoprotein IIB/IIIa receptor, which is essen-
tial for platelet aggregation [50]. The anti-platelet effects of
nitrates are also mediated by NO-driven cyclooxygenase/
prostacyclin 2 activation [51, 52]. In patients receiving intra-
venous GTN, >50 % inhibition of platelet aggregation has
been observed when tested in response to the pro-coagulant
stimuli adenosine diphosphate and thrombin [53]. While the
anti-platelet actions of nitrates could, in theory, be beneficial
in the context of an acute coronary syndrome (ACS) this is
not supported by clinical studies [54, 55]. In this con-
text, any impact of nitrates on platelet function is probably
overshadowed by the actions of potent anti-platelet drugs.
Another potentially beneficial action of nitrates is activa-
tion of ischemic mitochondrial preconditioning mechanisms
[56, 57]. It has been proposed that NO-induced reactive oxy-
gen species (ROS) could have a paradoxically beneficial ef-
fect on myocardial cells through activation of protein kinase C
and/or transient mitochondrial permeability transition pore
(mPTP) opening during ischemic reperfusion [58–60]. In fact,
nitrate-mediated ischemic preconditioning might act to alter
mode of presentation in patients with ACS. Analysis of data
from the Global Registry of Acute Coronary Events
(GRACE), including 52,693 patients from 123 centers in 14
countries revealed that patients on long-term nitrates who
present with ACS have a lower incidence of ST elevation
myocardial infarction and lower cardiac enzyme release than
those who are nitrate naïve (Fig. 2) [61]. While this data from
GRACE confirms similar findings of an earlier study, [62]
whether this link is causal remains to be determined [63].
Nitrates lose their clinical effect after 12–24 h of continu-
ous therapy, due to drug tolerance [64]. The cause of nitrate
tolerance is likely multi-factorial, and several theories have
been proposed [65]. At present, the prevailing hypothesis is
that tolerance results from superoxide (O2
−) formation, which
decreases NO bioavailability and causes uncoupling of nitric
oxide synthase (NOS), resulting in impaired NO-cGMP sig-
naling [34, 66]. Increased oxidative stress might also inhibit
ALDH-2 activity [67].
Mechanisms underlying nitrate tolerance not only result in
poor symptom control, but might also be potentially damaging
[68–70]. Accumulation of free radicals during long-term ni-
trate therapy has been linked to endothelial dysfunction, [71]
and increased vasoconstrictor sensitivity– providing a possi-
ble explanation for ‘rebound angina’ occurring from nitrate
withdrawal [72–74]. Thus, it appears nitrate-induced ROS
production might explain both protective and deleterious ef-
fects of nitrates [75]. Another potential problem is nitrate
‘pseudotolerance,’ resulting in cardiac autonomic dysfunction
due to increased neurohormonal response to vasodilatation
and activation of the renin-angiotensin-aldosterone system
[32, 76]. Further prospective clinical studies are warranted to
determine the long-term non-hemodynamic effects of nitrates,
and how these factors might influence overall cardiovascular
risk [3].
Clinical Trials
Nitrates have been demonstrated in clinical trials to improve
exercise tolerance, time to symptom onset, and time to ST-
segment depression during exercise testing in patients with
stable effort-induced angina [77]. In a meta-analysis per-
formed in 2009 to assess usefulness of nitrates for stable an-
gina, 51 randomized controlled, or crossover trials including a
total 3595 patients were identified [78]. The authors conclud-
ed that, overall, nitrate therapy reduced the number of angina
episodes by 2.45 per week, with greater effect on exercise
duration and ST depression from intermittent over continuous
dosing.
When taken 3–5 min before exercise testing, sublingual
GTN spray abolishes or delays onset of angina and ST-
Fig. 2 Mode of ACS presentation among patients receiving long-term
nitrates vs. nitrate naïve from the Global Registry of Acute Coronary
Events. Adapted from Ambrosio et al. EHJ; 2009
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segment depression with greater effect than placebo, [79] and
linear dose-response [80]. Improved exercise has also been
shown after 2 and 4 h of treatment with transdermal GTN,
but not beyond 24 h when therapy is uninterrupted [81].
Standard release ISDN increases time to angina during exer-
cise testing after the initial dose for up to 6–8 h, but, again,
efficacy is lost with sustained three or four times daily dosing
due to tolerance [82]. While three times daily buccal GTN
does not cause tolerance owing to its short half-life,
[83] it is important to note that partial cross-tolerance
blunts the hemodynamic response to sublingual GTN
when given to patients also taking sustained ISDN [84].
In a study comparing low and high doses of oral ISDN, there
was no added benefit of higher dose on exercise duration [85].
The Compliance With Oral Mononitrates in Angina
Pectoris Study (COMPASS) showed that patients were more
likely to adhere to once daily vs. twice daily ISMN dosing
regime, which overall resulted in less angina in this group
[86]. In a double-blind controlled study including 313 pa-
tients with stable effort-induced angina, significantly in-
creased exercise time was observed compared to placebo at
4 and 12 h after administration of extended release ISMN
[87]. In this study, ISMN at 120 mg or 240 mg doses re-
sulted in greater improvement in exercise tolerance than
lower doses, without development of tolerance or rebound
angina. Reduction in extent and severity of stress-induced
ischemic defects has also been shown after treatment with
this drug using Tc-99m-MIBI exercise single photon emis-
sion tomography (SPECT) [88, 89]. When evaluating ISMN
dosage on quality-of-life indices, better angina control seems
to result at higher doses, without significant increase in side
effects [90].
Drug Formulations, Dosage and Pharmacokinetics
Nitrates are rapidly absorbed from mucous membranes, the
gastrointestinal tract and skin. Onset of action, bioavailability,
and duration varies between nitrate preparations (Table 1).
Plasma GTN levels are initially high after sublingual admin-
istration, but quickly disappear [91]. GTN and ISDN undergo
extensive first-pass metabolism by the liver resulting in low
bioavailability; short-acting GTN is therefore ineffective if
swallowed. Oral ISMN is completely absorbed and, as it
avoids first pass metabolism, has 100 % bioavailability, lead-
ing to a more predictable dose-response with less variation in
plasma levels compared to other nitrates [92].
GTN is typically given for acute angina relief as a sublin-
gual tablet (0.3–0.6mg) or spray (0.4mg/dose). Its onset of
action is 1–3 min, and duration of action 10–30 min. Due to
the risk of orthostatic hypotension, patients are advised to take
GTN while seated. Doses can be repeated at 5 min intervals
until the pain is resolved, but prompt medical attention should
be sought when chest pain is severe or persists >15 min.
Buccal GTN and ISDN can also be given for acute angina
relief as sublingual tablet (2.5 - 15mg), chewable tablet
(5mg), or spray (1.25mg/dose). Buccal GTN and shorter-
acting ISDN preparations take several minutes longer than
sublingual GTN to work, but last for >1 h. When taken orally,
the onset of action of standard release ISDN is 15–30 min and
duration of action 3–6 h. For standard release ISMN this is
30–60 min and 6–8 h respectively [93, 94].
Nitrate tolerance can be avoided with eccentric dosing re-
gimes and use of extended release formulations, plus a daily
nitrate-free interval of at least 8–10 h [87, 95]. There is also
some evidence that folic acid, L-arginine, Vitamin C, and
other anti-oxidants can help to prevent nitrate tolerance and
endothelial dysfunction [71, 96, 97]. However, tolerance de-
velops with all currently available long-acting nitrates and
none can provide sustained 24 h prophylaxis [98]. A typical
starting dose of extended release ISMN is 30 mg or 60 mg
once daily, which can be up-titrated to 120 or 240 mg if re-
quired. A single dose of extended release ISMN provides
cover for up to 12–14 h. When transdermal GTN is used,
tolerance is avoided by interrupting patches with regular ni-
trate free (patch-off) breaks [99, 100]. Although nighttime
patch removal can circumvent nitrate tolerance, this ap-
proach does not provide prophylaxis against nocturnal
angina; and might actually worsen angina during this
period due to the rebound effect of nitrate withdrawal,
and ‘zero-hour’ effect resulting in worsened exercise tolerance
in the morning before patch application [65]. Rebound angina
is not seen with long-acting oral nitrates.
Side Effects and Tolerability
Headache is the most common side effect of nitrates, which
prevents its use 10 % of patients [101]. Headaches occurring
within the first hour of nitrate administration are usually due to
vasodilation, which can be avoided by use of a low starting
dose with slow up-titration [102]. Simple headaches typically
disappear within 1–2 weeks of treatment, and co-
administration with aspirin given for secondary prevention
can help to reduce this symptom. Nitrates can, however, also
trigger migraine and other types of headache [103]. Other
common side effects of nitrates are: light-headedness, flush-
ing, and postural hypotension with risk of syncope (Table 2).
Drug Safety and Cautions
The safety of nitrates has been demonstrated during its
many years of clinical use. Risk of orthostatic hypoten-
sion is greater in the elderly due to age-related auto-
nomic dysfunction. If syncope occurs, nitrates should
be discontinued. Nitrates are contra-indicated in patients
with hypertrophic cardiomyopathy, and used with caution in
aortic stenosis due to risk of worsening outflow tract
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gradient. Other absolute contraindications to nitrates are co-
administration with phosphodiesterase-5 (PDE-5) inhibitors
(e.g. sildenafil) due to the risk of profound hypotension, and
closed angle glaucoma. Methemoglobinemia is a rare adverse
effect, which has been reported with large nitrate doses. Safety
of nitrates in pregnancy and breastfeeding has not been eval-
uated, and therefore should be avoided when possible.
Nicorandil
Nicorandil (N-[2-(Nitro-oxy) ethyl]-3-pyridine carboxamide)
is a balanced vasodilator, which affects both venous and arte-
rial beds. Its chemical structure consists of a nicotinamide
derivative combined with nitrate moiety. Overall, nicorandil
is similarly effective for angina prophylaxis to long-acting
nitrates and other conventional anti-anginal drugs, however
it does not cause tolerance and might offer added prognostic
benefit [104, 105].
Mechanism of Action
Nicorandil exerts two distinct anti-angina mechanisms, acting
as both: (1) NO donor, and (2) K+ATP channel opener [106].
The nitrate-like action of nicorandil accounts for the majority
of its clinical efficacy at therapeutic concentrations. [107].
Bioactivation of nicorandil involves denitration via the
nicotinamide/ nicotinic acid pathway [108]. Similar to ni-
trates, NO acts via cGMP signaling pathways within vascular
smooth muscle cells causing peripheral and coronary vasodi-
latation [10]. In addition, its action on K+ATP channels results
in vascular smooth cell hyperpolarization and closure of L-
type voltage gated calcium channels, [109] which acts to dilate
both coronary microvessels and peripheral resistance arteries
[110, 111].
Table 1 Prescribing nitrates and nicorandil
Drug First-pass effect Pro-drug Usual dose Frequency Max dose Onset Duration
Nitrates
Glycerol-trinitrate (GTN)
Sublingual tab No Yes 0.3–0.6 mg As needed (every 5 mins) 1.5 mg 1–3 min 10–30 min
Sublingual spray No Yes 0.4 mg/dose As needed (every 5 mins) 1.5 mg 1–3 min 10–30 min
Patch No Yes 0.1–0.8 mg/h 1 daily (12 h on/ 12 h off) 1 patch/ day 30 mins 8–14 h
Isosorbide dinitrate (ISDN)
Sublingual tab No Yes 2.5 mg Repeated as needed 15 mg 3–4 min 1 h
Chewable tab No Yes 5 mg Repeated as needed 15 mg 3–4 min 1 h
Standard release Yes Yes 30–120 mg 2–3 daily (last dose 6pm) 240 mg/ day 15–30 min 3–6 h
Extended relsease Yes Yes 20–40 mg 2 daily (8am and 3pm) 80 mg/ day 30–60 min 12–14h
Isosorbide mononitrate (ISMN)
Standard release No Yes 10–40 mg 2 daily (8am and 3pm) 120 mg/ day 30–60 min 6–8 h
Extended release No Yes 60–240 mg Once daily 240 mg/ day 30–60 min 12–14h
K+ATP agonist
Nicorandil No Yes 10–20 mg 2 daily (8am and 3pm) 60 mg/ day 30–60 min 12 h
Table 2 Side effects of nitrates
and nicorandil Drug Side-effects Contraindications
Nitrates
>10: headache Hypotension
Cardiogenic shock
0.1–10 %: dizziness, flushing, nausea, vomiting,
light-headedness, orthostatic hypotension,
syncope, contact dermatitis (patch)
Hypertrophic cardio myopathy severe
Aortic stenosis PDE-5 inhibitors closed
angle glaucoma
Rare: methaemoglobinaemia
Nicorandil
Common: as per nitrates As per nitrates
Rare: skin and gastric ulceration
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Hemodynamic Effects
The hemodynamic effects of nicorandil result in balanced
offloading of the ventricles through reduction in preload and
afterload, and improved coronary flow due to lowered coro-
nary arterial resistance [112, 113]. Nicorandil dilates coronary
arteries by 10–20 % in patients with coronary atherosclerosis,
mostly because of its nitrate-like effect [114]. Coronary dila-
tation induced by nicorandil occurs in both normal and dis-
eased vessel segments, [115] with potentially greater effect on
stenotic areas than nitrates [116]. In one study, 40 mg of
nicorandil administered via oral or sublingual routes led to
significant reduction in left ventricular end-diastolic pressure
after 15 mins, and total peripheral resistance was reduced by
19 % [117]. Similar to nitrates, a mild dose-dependent baro-
ceptor reflex tachycardia can also occur. Nicorandil does not
directly affect cardiac conduction or contractility.
Non-Hemodynamic Effects and Cardiovascular Risk
The actions of nicorandil on K+ATP channels are thought to
confer cardioprotection through activation of pathways linked
to ischemic preconditioning [118, 119]. Nicorandil also ap-
pears to have a protective effect on endothelial function,
[120–123] and might help to stabilize coronary plaque
[124]. Several theories have been proposed to explain poten-
tial cardioprotective properties of nicorandil. One hypothesis
is that KATP channel opening mimics actions of endogenous
adenosine release, thereby shortening myocardial cell action
potentials, and reducing Ca2+ overload and cellular energy
demands [125, 126]. However, increasing evidence highlights
the role of mitochondrial KATP channels in mediating ische-
mic preconditioning due to nicorandil, [127, 128] and its po-
tential to prevent oxidative damage through inhibition of
mPTP activation during ischemic reperfusion injury [11,
129]. Nicorandil might also prevent myocardial ischemic re-
perfusion injury through suppression of endoplasmic reticu-
lum stress-induced apoptotic cell death through the PI3K/Akt
pathway [130].
Data from several randomized controlled trials suggest that
treatment with nicorandil might improve long-term clinical
outcomes. This potential benefit was first suggested by the
Impact of Nicorandil in Angina (IONA) study [131]. In
IONA, 5126 patients with stable angina were randomized to
receive 20 mg of nicorandil or placebo, with mean follow up
of 1.6 ± 0.5 yrs. Results of IONA showed a significant reduc-
tion in the composite end-point of death due to coronary heart
disease, non-fatal myocardial infarction or unplanned hospital
admission with chest pain in the treatment group 13.1 % vs.
placebo 15.5 %, HR 0.83, p = 0.014 (Fig. 2). This observation
occurred independently of any impact from subgroup status,
[132] however IONA was underpowered to show statistical
significance for the secondary outcome of coronary heart
disease mortality or non-fatal myocardial infarction, and the
individual components of the composite end point did not dif-
fer significantly between the two study groups [133]. Further
prognostic evidence for nicorandil comes from the Japanese
Coronary Artery Disease (JCAD) study [134]. JCAD was a
multi-centre prospective observational study, which compared
outcomes of 2558 patients with ≥75 % epicardial artery steno-
sis treated with nicorandil vs. matched controls. The follow up
period was 2.7 yrs. Results of JCAD showed a 35 % reduction
in all causemortality (HR 0.65, p = 0.0008) and 56% reduction
in cardiac death (HR 0.44, p < 0.0001) in the treatment group.
There is also some evidence that nicorandil reduces risk of
non-sustained ventricular and supraventricular arrhythmia
when used in patients with unstable angina [135]. However,
whether or not nicorandil provides any prognostic benefit in
addition to its anti-angina effects has yet to be determined
conclusively, and therefore the current indication for its use
in stable angina is for symptomatic relief.
Clinical Efficacy
The clinical efficacy of nicorandil for treatment of effort-
induced stable angina has been evaluated by a number of
clinical trials. Open label, placebo-controlled and comparative
studies have demonstrated reduction in frequency of angina
episodes and improvement of exercise tolerance following
treatment with nicorandil [136–142]. In one placebo-
controlled study, time to angina during exercise testing was
increased by 38 % at 2 h and 23 % at 12 h after two-weeks of
nicorandil [143]. A meta-analysis of 20 prospective controlled
trials showed that, overall, nicorandil is equally effective to
standard angina treatment [144].
Positive efficacy data exist for nicorandil when compared to
long-acting nitrates, [145, 146] calcium channel blockers, [147,
148] and beta-blockers [149–151]. The Study of Nicorandil in
Angina Pectoris in the Elderly (SNAPE), which included 194
patients, reported similar improvement in time to angina
and time to ST depression during symptom-limited bicycle
exercise testing after 4 weeks of nicorandil vs. ISMN [152].
Comparison of the Anti-ischemic and Anti-anginal Effects of
Nicorandil and Amlodipine in Patients with Symptomatic
Stable Angina Pectoris (SWAN) study was a multi-centre, dou-
ble-blind, randomized study of 121 patients from 25 centers in
Austria and Switzerland [153]. SWAN showed comparable
performance and tolerability for these two angina drugs.
Dosage and Pharmacokinetics
Nicorandil is rapidly and almost completely absorbed via the
gastrointestinal tract, reaching maximal plasma concentration
after 30–60min, and steady-state levels following 4–5 days of
standard therapy. Gastrointestinal absorption is delayed, but
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not decreased by food. Its half-life is roughly 52 mins.
Nicorandil does not undergo first-pass metabolism, and dis-
plays a linear dose-to-plasma concentration relationship at
doses of 5 - 40mg. Its oral bioavailablity is >75 %, with
<20 % of the drug excreted in the urine. Nicorandil circulates
largely unbound to albumin or other plasma proteins. Its anti-
angina effects last approximately 12 h, necessitating twice-
daily dosage. Pharmacokinetic properties are not significantly
effected by age, chronic liver and/or renal disease [108, 154].
A usual starting dose of nicorandil is 10 mg twice daily, or
5 mg for patients susceptible to headache. The lowest effective
dose is recommended to avoid potential side effects, especial-
ly in the elderly. The therapeutic dose is typically 10 - 20 mg
twice daily, and maximum dose 30 mg twice daily. Unlike
nitrates, tolerance to nicorandil does not tend to occur, proba-
bly because of its dual mode of action [155, 156]. However, an
attenuated response during exercise testing was reported in
one study after 2 weeks of sustained therapy. Nicorandil does
not cause rebound angina [157].
Side Effects and Tolerability
Nicorandil is well tolerated by most patients. Less than 10 %
of patients report side-effects after 30 days of treatment, and
roughly 70 % remain on nicorandil at 1 year [158]. Similar to
nitrates, headache is the most common side effect to
nicorandil, occurring in roughly one third of patients. Other
relatively common side effects are: dizziness, flushing, mal-
aise and gastro-intestinal upset. Rarely, nicorandil can cause
gastrointestinal, skin, mucosal, or eye ulceration [159, 160].
Nicorandil should be stopped immediately if ulceration
occurs.
Drug Safety and Cautions
Similar to nitrates, nicorandil is contraindicated in the setting
of compromised blood pressure and must not be used in con-
junction with PDE-5 inhibitors due to the risk of severe hypo-
tension resulting from this dangerous drug combination. Due
to risk of gastro-intestinal ulceration, caution is advised when
prescribing nicorandil for patients also taking corticosteroids.
Although the overall safety of nicorandil has been demonstrat-
ed by numerous clinical trials, including the Prescription
Event Monitoring (PEM) study, [161] recent review by the
European drug regulatory agencies have lead the manufactur-
er to highlight several additional contraindications and warn-
ings. The manufacturer now states that gastro-intestinal ulcers
can progress to perforation, hemorrhage, fistula or abscess –
and that patients with diverticular disease might be at higher
risk of these severe complications. Ulcers caused by
nicorandil do not respond to conventional ulcer treatment,
including surgery, and therefore if ulcers occur in any part of
the body nicorandil must be stopped. Actions of nicorandil on
K+ATP channels are antagonized by some sulphonyureas, in-
cluding glibenclamide and glimepiride [162]. The effects of
nicorandil during pregnancy, breast-feeding and on fertility
have not been studied in humans and therefore this agent
should be avoided in this context.
Coronary Spasm and Microvascular Angina
Although calcium channel blockers are the drug of choice for
the treatment of angina resulting from coronary artery spasm,
vasospastic angina can also be successfully treated with ni-
trates and nicorandil [163, 164]. However, recent data from
the Japanese coronary spasm association registry indicates a
potentially higher incidence of major adverse cardiac events
(MACE) when these two drugs are used together for treatment
of chronic vasospastic angina (Fig. 3) [165]. Nitrates have
limited use in patients with microvascular angina owing to
its relatively small vasodilatory effect on small resistance ves-
sels [166]. In clinical practice, however, they are useful in
roughly 50 % of patients [167, 168]. Nicorandil has a more
pronounced effect on the coronary microcirculation than ni-
trates, and therefore might be better suited for patients with
microvascular angina, including those with microvascular
spasm [169–172].
Conclusion
Long-acting nitrates and nicorandil are effective drugs for
treatment of stable effort-induced angina, which are recom-
mended ‘second-line’ according to current European guide-
lines. These pharmacological agents are particularly useful for
patients who are able to tolerate short-acting GTN without
side effects. When compared to other second-line anti-angina
drugs (e.g. ranolazine and ivabradine), nitrates and nicorandil
Fig. 3 Cumulative incidence of major adverse cardiac events (MACE)
occurring in patients treated with nitrates and/ or nicorandil for vasospatic
angina in the multi-centre registry study of the Japanese Coronary spasm
association. Adapted from Takahashi et al. EHJ; 2014
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are on the whole similarly effective to these agents, and choice
is guided by individual factors such as co-morbidities, contra-
indications, availability and patient preference [133]. A major
limitation of nitrate therapy is drug tolerance. While tolerance
can be avoided by dosing regimes that incorporate a nitrate-
free interval, the risk of nocturnal angina and rebound angina
remains. Further studies are warranted to determine the long-
term impact of nitrates on cardiovascular outcomes. One ad-
vantage of nicorandil over long-acting nitrates is that tolerance
does not occur, but there are other potential adverse effects of
this drug to be considered, including, rarely, skin or gastro-
intestinal ulceration. There is also some evidence from large
prospective clinical trials to suggest that nicorandil might im-
prove long-term clinical outcomes. However, further research
is needed to understand the potential cardioprotective mecha-
nisms of nicorandil and to assess its impact on long-term sur-
vival. While each drug has potential advantages and limita-
tions, long-acting nitrates and nicorandil are important phar-
macological agents for management of chronic stable angina
triggered by obstructive atherosclerotic coronary artery dis-
ease, as well as microvascular angina and epicardial coronary
artery spasm.
Acknowledgments JMT is supported by a Wellcome Trust research
training fellowship (104492/Z/14/Z).
Compliance with Ethical Standards
Conflicts of Interest None.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. MurrellW. Nitro-glycerine as a remedy for angina pectoris. Lancet
Elsevier. 1879;113:225–7.
2. Task ForceMembers,Montalescot, G, Sechtem, U, Achenbach, S,
Andreotti, F, Arden, C, et al. 2013 ESC guidelines on the man-
agement of stable coronary artery disease: the Task Force on the
management of stable coronary artery disease of the European
Society of Cardiology. Eur Heart J. 2013. pp. 2949–3003.
3. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas
AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
guideline for the diagnosis and Management of Patients with
Stable Ischemic Heart Disease. J Am Coll Cardiol Elsevier Inc.
2012;60:e44–e164.
4. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N
Engl J Med. 1998;338:520–31.
5. Murad F. Discovery of some of the biological effects of nitric
oxide and its role in cell signaling. Biosci Rep. 2005;24:452–74.
6. Ignarro LJ. Nitric oxide: a unique endogenous signaling molecule
in vascular biology. Biosci Rep Kluwer Acad Publishers-Plenum
Publishers. 1999;19:51–71.
7. Furchgott RF. Endothelium-derived relaxing factor: discovery,
early studies, and identification as nitric oxide. Biosci Rep
Kluwer Acad Publishers-Plenum Publishers. 1999;19:235–51.
8. Thatcher GRJ, Nicolescu AC, Bennett BM, Toader V. Nitrates and
no release: contemporary aspects in biological and medicinal
chemistry. Free Radic Biol Med. 2004;37:1122–43.
9. Gori T, Parker JD. Nitrate-induced toxicity and preconditioning. J
Am Coll Cardiol. 2008;52:251–4.
10. Kukovetz WR, Holzmann S, Braida C, Pöch G. Dual mechanism
of the relaxing effect of nicorandil by stimulation of cyclic GMP
formation and by hyperpolarization. J Cardiovasc Pharmacol.
1991;17:627–33.
11. Horinaka DS. Use of nicorandil in cardiovascular disease and its
optimization. Drugs Springer Int Publ. 2011;71:1105–19.
12. Tarkin JM, Kaski JC. Pharmacological treatment of chronic stable
angina pectoris. Clin Med Royal Coll Physicians. 2013;13:63–70.
13. Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of
antianginal drugs used as add-on therapy in patients with stable
angina: a systematic review and meta-analysis. Eur J Prev Cardiol.
2015;22:837–48.
14. Lanza GA, Parrinello R, Figliozzi S. Management of microvascu-
lar angina pectoris. Am J Cardiovasc drugs. Springer International
Publishing. 2014;14:31–40.
15. Maseri A, Chierchia S, Kaski JC. Mixed angina pectoris. AJC.
1985;56:30E–3E.
16. Kaski JC. Management of vasospastic angina–role of nicorandil.
Cardiovasc Drugs Ther. 1995;9(Suppl 2):221–7.
17. Fung HL, Chung SJ, Bauer JA, Chong S, Kowaluk EA.
Biochemical mechanism of organic nitrate action. AJC.
1992;70:4B–10B.
18. Heidenreich PA,McDonald KM, Hastie T, Fadel B, Hagan V, Lee
BK, et al. Meta-analysis of trials comparing β-blockers, calcium
antagonists, and nitrates for stable angina. JAMAAmMed Assoc.
1999;281:1927–36.
19. Münzel T, Meinertz T, Tebbe U, Schneider HT, Stalleicken D,
Wargenau M, et al. Efficacy of the long-acting nitro vasodilator
pentaerithrityl tetranitrate in patients with chronic stable angina
pectoris receiving anti-anginal background therapy with beta-
blockers: a 12-week, randomized, double-blind, placebo-
controlled trial. Eur Heart J. 2014;35:895–903.
20. Munzel T. Physiology and pathophysiology of vascular signaling
controlled by cyclic guanosine 3″,5-^cyclic monophosphate-
dependent protein kinase. Circulation. 2003;108:2172–83.
21. Palmer R, Ferrige AG, Moncada S. Nitric oxide release accounts
for the biological activity of endothelium-derived relaxing factor.
Nature. 1987;327:524–6.
22. Suk-Jae C, Ho-Leung F. Relationship between nitroglycerin-
induced vascular relaxation and nitric oxide production: probes
with inhibitors and tolerance development. Biochem Pharmacol.
1993;45:157–63.
23. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH,
Alexander RW, et al. Paradoxical vasoconstriction induced by
acetylcholine in atherosclerotic coronary arteries. N Engl J Med.
1986;315:1046–51.
24. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ, Ganz P,
et al. The effect of atherosclerosis on the vasomotor re-
sponse of coronary arteries to mental stress. N Engl J Med.
1991;325:1551–6.
25. Thadani U. Oral nitrates: more than symptomatic therapy in cor-
onary artery disease? Cardiovasc Drugs Ther. 1997;11(Suppl 1):
213–8.
Cardiovasc Drugs Ther
26. Mayer B, Beretta M. The enigma of nitroglycerin bioactivation
and nitrate tolerance: news, views and troubles. Br J Pharmacol.
2009;155:170–84.
27. Kleschyov AL. Does nitric oxide mediate the vasodilator activity
of nitroglycerin? Circ Res. 2003;93:104e–112.
28. Nunez C. Discrepancies between nitroglycerin and NO-releasing
drugs on mitochondrial oxygen consumption, vasoactivity, and
the release of NO. Circ Res. 2005;97:1063–9.
29. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic
mechanism of nitroglycerin bioactivation. Proc. Natl. Acad. Sci.
U.S.A. Natl Acad Sci. 2002;99:8306–11.
30. Chen Z, Stamler JS. Bioactivation of nitroglycerin by the mito-
chondrial aldehyde dehydrogenase. Trends Cardiovasc Med.
2006;16:259–65.
31. Li Y. Mitochondrial aldehyde dehydrogenase-2 (ALDH2)
Glu504Lys polymorphism contributes to the variation in efficacy
of sublingual nitroglycerin. J Clin Investig. 2006;116:506–11.
32. Munzel T, Daiber A, Gori T. Nitrate therapy: new aspects
concerning molecular action and tolerance. Circulation.
2011;123:2132–44.
33. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P,
Sydow K, et al. Oxidative stress and mitochondrial aldehyde de-
hydrogenase activity: a comparison of pentaerythritol tetranitrate
with other organic nitrates. Mol Pharmacol. 2004;66:1372–82.
34. Daiber A, Wenzel P, Oelze M, Münzel T. New insights into
bioactivation of organic nitrates, nitrate tolerance and cross-toler-
ance. Clin Res Cardiol. 2007;97:12–20.
35. Torfgård KE, Ahlner J. Mechanisms of action of nitrates.
Cardiovasc Drugs Ther. 1994;8:701–17.
36. Morgado M, Cairrão E, Santos-Silva AJ, Verde I. Cyclic
nucleotide-dependent relaxation pathways in vascular smooth
muscle. Cell Mol Life Sci. 2012;69:247–66.
37. Abrams J. Beneficial actions of nitrates in cardiovascular disease.
Am J Cardiol. 1996.
38. Feldman RL, Pepine CJ, Conti CR. Magnitude of dilatation of
large and small coronary arteries of nitroglycerin. Circulation.
1981;64:324–33.
39. Münzel T, Gori T. Nitrate therapy and nitrate tolerance in patients
with coronary artery disease. Curr Opin Pharmacol Elsevier Ltd.
2013;13:251–9.
40. Tousoulis D, Davies GJ, Toutouzas PC. Vasomotion of coronary
arteries: from nitrates to nitric oxide. Cardiovasc Drugs Ther.
Kluwer Academic Publishers. 1999;13:295–300.
41. Abrams J. Mechanisms of action of the organic nitrates in
the treatment of myocardial ischemia. Am J Cardiol.
1992;70:B30–42.
42. BrownBG, Lee AB, Bolson EL, DodgeHT. Reflex constriction of
significant coronary stenosis as a mechanism contributing to is-
chemic left ventricular dysfunction during isometric exercise.
Circn Lippincott Williams & Wilkins. 1984;70:18–24.
43. Fujita M, Yamanishi K, Inoko M. Preferential dilation of recipient
coronary arteries of the collateral circulation by intracoronary ad-
ministration of nitroglycerin. J Am Coll Cardiol 1994.
44. Brown BG, Bolson E, Petersen RB, Pierce CD, Dodge HT. The
mechanisms of nitroglycerin action: stenosis vasodilatation as a
major component of the drug response. Circulation. 1981;64:
1089–97.
45. SidhuM, BodenWE, Padala SK, Cabral K, Buschmann I. Role of
short-acting nitroglycerin in the management of ischemic heart
disease. DDDT. 2015;4793–13.
46. Fallen EL, Nahmias C, Scheffel A, Coates G, Beanlands R,
Garnett ES. Redistribution of myocardial blood flow with topical
nitroglycerin in patients with coronary artery disease. Circ
Lippincott Williams & Wilkins. 1995;91:1381–8.
47. Horwitz LD, Gorlin R, Taylor WJ, Kemp HG. Effects of nitro-
glycerin on regional myocardial blood flow in coronary artery
disease. J Clin Invest Am Soc Clin Invest. 1971;50:1578–84.
48. Imhof PR, Sieber A, Hodler J, Müller P, Ott B, Fankhauser P, et al.
Plasma concentrations and haemodynamic effects of nitroglycerin
during and after intravenous infusion in healthy volunteers. Eur J
Clin Pharmacol. 1982;23:99–106.
49. Hampton JR, Harrison MJ, Honour AJ, Mitchell JR. Platelet be-
haviour and drugs used in cardiovascular disease. Cardiovasc Res.
1967;1:101–7.
50. Zhou R-H, Frishman WH. The antiplatelet effects of nitrates: is it
of clinical significance in patients with cardiovascular disease?
Cardiol Rev. 2010;18:198–203.
51. Salvemini D, Currie MG, Mollace V. Nitric oxide-mediated cy-
clooxygenase activation. A key event in the antiplatelet effects of
nitrovasodilators. J Clin Investig. 1996;97:2562–8.
52. Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates
and related nitroso compounds in vitro and in vivo and their rele-
vance to cardiovascular disorders. J Am Coll Cardiol. 1991;18:
1529–36.
53. Diodati J, Theroux P, Latour JG, Lacoste L, Lam JY, Waters D.
Effects of nitroglycerin at therapeutic doses on platelet aggrega-
tion in unstable angina pectoris and acute myocardial infarction.
AJC. 1990;66:683–8.
54. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate
singly and together on 6-week mortality and ventricular function
after acute myocardial infarction. Gruppo Italiano per lo Studio
della Sopravvivenza nell'infarto Miocardico. Lancet. 1994;343:
1115–22.
55. ISIS-4: a randomised factorial trial assessing early oral captopril,
oral mononitrate, and intravenous magnesium sulphate in 58,050
patients with suspected acute myocardial infarction. ISIS-4
(Fourth International Study of Infarct Survival) Collaborative
Group. Lancet. 1995;345:669–85.
56. Jneid H, ChandraM, AlshaherM, Hornung CA, TangX-L, Leesar
M, et al. Delayed preconditioning-mimetic actions of nitroglycerin
in patients undergoing exercise tolerance tests. Circulation.
2005;111:2565–71.
57. Hill M, Takano H, Tang XL, Kodani E, Shirk G, Bolli R.
Nitroglycerin induces late preconditioning against myocardial in-
farction in conscious rabbits despite development of nitrate toler-
ance. Circulation. 2001;104:694–9.
58. Gori T, Di Stolfo G, Sicuro S, Dragoni S, Lisi M, Forconi S, et al.
Nitroglycerin protects the endothelium from ischaemia and reper-
fusion: human mechanistic insight. Br J Clin Pharmacol. 2007;64:
145–50.
59. Banerjee S, Tang XL, Qiu Y, Takano H, Manchikalapudi S, Dawn
B, et al. Nitroglycerin induces late preconditioning against myo-
cardial stunning via a PKC-dependent pathway. Am J Phys.
1999;277:H2488–94.
60. Murphy E. Primary and secondary signaling pathways in early
preconditioning that converge on the mitochondria to produce
cardioprotection. Circ Res. 2004;94:7–16.
61. Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M,
Zuchi C, et al. Chronic nitrate therapy is associated with different
presentation and evolution of acute coronary syndromes: insights
from 52 693 patients in the global registry of acute coronary
events. Eur Heart J. 2010;31:430–8.
62. Timóteo AT, Mamede A, Ferreira ML, Serra J. A terapêutica
crónica com nitratos está associada a uma diferente apresentação
clínica de síndroma coronária aguda? 2007.
63. Giuseppe C, Paul J, Hans-Ulrich I. Use of nitrates in ischemic
heart disease. Expert Opin Pharmacother. 2015;16:1567–72.
64. Zimrin D, Reichek N, BoginKT, AurigemmaG,Douglas P, Berko
B, et al. Antianginal effects of intravenous nitroglycerin over 24
hours. Circulation. 1988;77:1376–84.
Cardiovasc Drugs Ther
65. Thadani U. Challenges with nitrate therapy and nitrate tolerance:
prevalence, prevention, and clinical relevance. Am J Cardiovasc
Drugs. 2014;14:287–301.
66. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis.
Circulation. 2002;106:2510–3.
67. DiFabio J, Ji Y, Vasiliou V, Thatcher GRJ, Bennett BM. Role of
mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol
Pharmacol Am Soc Pharmacol and Exp Ther. 2003;64:1109–16.
68. Gori T, Daiber A. Non-hemodynamic effects of organic nitrates
and the distinctive characteristics of pentaerithrityl tetranitrate.
Am J Cardiovasc Drugs Lippincott Williams & Wilkins. 2009;9:
7–15.
69. Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata
N, et al. Long-term nitrate treatment increases cardiac events in
patients with healed myocardial infarction. Secondary Prevention
Group Jpn Circ J. 1996;60:779–88.
70. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C.
Long-term nitrate use may be deleterious in ischemic heart dis-
ease: a study using the databases from two large-scale
postinfarction studies. Multicenter myocardial ischemia research
group. Am Heart J. 1999;138:577–85.
71. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy
with isosorbide-5-mononitrate causes endothelial dysfunction in
humans: evidence of a free-radical-mediated mechanism. J Am
Coll Cardiol. 2007;49:1289–95.
72. Caramori PR, Adelman AG, Azevedo ER, Newton GE, Parker
AB, Parker JD. Therapy with nitroglycerin increases coronary
vasoconstriction in response to acetylcholine. J Am Coll Cardiol.
1998;32:1969–74.
73. Munzel T, Mollnau H, Hartmann M, Geiger C, Oelze M,
Warnholtz A, et al. Effects of a nitrate-free interval on tolerance,
vasoconstrictor sensitivity and vascular superoxide production. J
Am Coll Cardiol. 2000;36:628–34.
74. Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin
withdrawal increases endothelium-dependent vasomotor response
to acetylcholine. J Am Coll Cardiol. 2001;37:505–9.
75. Gori T. The puzzle of nitrate tolerance: pieces smaller than We
thought? Circulation. 2002;106:2404–8.
76. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A,
Nohara R, et al. Baroreflex sensitivity and heart rate variability in
the identification of patients at risk for life-threatening arrhyth-
mias: implications for clinical trials. Circulation. 2001;103:
2072–7.
77. Nitrates as an Integral Part of Optimal Medical Therapy and
Cardiac Rehabilitation for Stable Angina: Review of Current
Concepts and Therapeutics. 2015. pp. 1–9.
78. Wei J, Wu T, Yang Q, Chen M, Ni J, Huang D. Nitrates for stable
angina: a systematic review andmeta-analysis of randomized clin-
ical trials. International journal of cardiology. Elsevier Ireland Ltd.
2011;146:4–12.
79. Kimchi A, Lee G, Amsterdam E, Fujii K, Krieg P. Increased ex-
ercise tolerance after nitroglycerin oral spray: a new and effective
therapeutic modality in angina pectoris. Circulation 1983.
80. Thadani, Thomas Wittig. A randomized, double-blind, placebo-
controlled, crossover, dose-rangingmulticenter study to determine
the effect of sublingual nitroglycerin spray on exercise capacity in
patients with chronic stable angina. Clinical Medicine Insights:
Cardiology. 2012:6;87–95.
81. Bassan MM, Rogel S. A comparison of the day-long antianginal
effectiveness of nitroglycerin patches with that of three-times-
daily isosorbide dinitrate: a double-blind study using dose titra-
tion. Eur Heart J. 1992;13(9):1265–70.
82. Bassan MM. The daylong pattern of the antianginal effect of long-
term three times daily administered isosorbide dinitrate. J AmColl
Cardiol. 1990:16(4);936–40.
83. Parker JO, Vankoughnett KA. Farrell B. The American Journal of
Cardiology: Comparison of buccal nitroglycerin and oral
isosorbide dinitrate for nitrate tolerance in stable angina
pectoris. Am J cardiol. 1985;56(12):724–8.
84. Manyari DE, Smith ER, Spragg J. Isosorbide dinitrate and glyc-
eryl trinitrate: demonstration of cross tolerance in the capacitance
vessels. Am J Cardiol. 1985;55(8):927–31.
85. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide
dinitrate in angina pectoris: comparison of duration of action an
dose-response relation during acute and sustained therapy. AJC.
1982;49:411–9.
86. Kardas P. Comparison of once daily versus twice daily oral nitrates
in stable angina pectoris. Am J Cardiol. 2004;94:213–6.
87. Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim
R, et al. Efficacy and safety of extended-release isosorbide
mononitrate for stable effort angina pectoris. AJC.
1993;72:1249–56.
88. Göller V, Clausen M, Henze E, Giesler M, Schmidt A, Kochs M,
et al. Reduction of exercise-induced myocardial perfusion defects
by isosorbide-5-nitrate: assessment using quantitative Tc-99m-
MIBI-SPECT. Coron Artery Dis. 1995;6:245–9.
89. Lewin HC, Hachamovitch R, Harris AG, Williams C, Schmidt J,
Harris M, et al. Sustained reduction of exercise perfusion defect
extent and severity with isosorbide mononitrate (Imdur) as dem-
onstrated by means of technetium 99m sestamibi. J Nucl Cardiol.
2000;7:342–53.
90. Zwinderman AH, Cleophas TJ, van der Sluijs H, Niemeyer MG,
Buunk BP, van der Wall EE. Comparison of 50-mg and 100-mg
sustained-release isosorbide mononitrate in the treatment of stable
angina pectoris: effects on quality-of-life indices. Dutch
mononitrate quality of life (DUMQOL) study group. Angiology.
1999;50:963–9.
91. Bogaert MG. Pharmacokinetics of organic nitrates in man: an
overview. Eur Heart J. The Oxford University Press; 1988;9:33–7.
92. Thadani U, Hamilton SF, Olson E, Anderson JL. Duration of
effects and tolerance of slow-release isosorbide-5-mononitrate
for angina pectoris. Am J Cardiol. 1987;59:756–62.
93. Kaski JC, Hayward C, Mahida S, Baker S, Khong T. Tamargo J.
OUP Oxford: Drugs in Cardiology; 2010.
94. Avanzas P, Kaski JC. Pharmacological treatment of chronic stable
angina pectoris. Avanzas P, Kaski JC, editors. Cham:
Springer; 2015.
95. Parker JO. Eccentric dosing with isosorbide-5-mononitrate in an-
gina pectoris. AJC Elsevier. 1993;72:871–6.
96. Gori T, Burstein JM, Ahmed S,Miner SE, Al-Hesayen A, Kelly S,
et al. Folic acid prevents nitroglycerin-induced nitric oxide syn-
thase dysfunction and nitrate tolerance: a human in vivo study.
Circulation. 2001;104:1119–23.
97. Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH.
The effect of supplemental L-arginine on tolerance development
during continuous transdermal nitroglycerin therapy. J Am Coll
Cardiol. 2002;39:1199–203.
98. Thadani U, Lipicky RJ. Short and long-acting oral nitrates for
stable angina pectoris. Cardiovasc Drugs Ther. 1994;8:611–23.
99. Fox KM, Dargie HJ, Deanfield J, Maseri A. Avoidance of toler-
ance and lack of rebound with intermittent dose titrated transder-
mal glyceryl trinitrate. The transdermal nitrate investigators. Br
Heart J. 1991;66:151–5.
100. Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris.
AJC. 1984;54:471–6.
101. Thadani U, Rodgers T. Side effects of using nitrates to treat angina.
Expert Opin Drug Saf. 2006;5:667–74.
102. Cleophas TJM, Niemeyer MG, van der Wall EE. Nitrate-induced
headache in patients with stable angina pectoris: beneficial effect
of starting on a low dosage. Am J Ther SAGE Publications.
1996;3:802–6.
Cardiovasc Drugs Ther
103. Bagdy G, Riba P, Kecskeméti V, Chase D, Juhász G. Headache-
type adverse effects of NO donors: vasodilation and beyond. Br J
Pharmacol. 2010;160:20–35.
104. Gomma DAH, Purcell HJ, Fox KM. Potassium Channel openers
in myocardial ischaemia. Drugs Springer Int Publ. 2001;61:
1705–10.
105. Goldschmidt M, Landzberg BR, Frishman WH. Nicorandil: a po-
tassium channel opening drug for treatment of ischemic heart dis-
ease. J Clin Pharmacol. 1996;36:559–72.
106. Taira N. Nicorandil as a hybrid between nitrates and potassium
channel activators. AJC. 1989;63:18J–24J.
107. Kukovetz WR, Holzmann S, Pöch G. Molecular mechanism of
action of nicorandil. J Cardiovasc Pharmacol. 1992;20(Suppl 3):
S1–7.
108. Frydman A. Pharmacokinetic profile of nicorandil in humans: an
overview. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S34–44.
109. Sumimoto K, Domae M, Yamanaka K, Nakao K, Hashimoto T,
Kitamura K, et al. Actions of nicorandil on vascular smooth mus-
cles. J Cardiovasc Pharmacol. 1987;10(Suppl 8):S66–75.
110. Brodmann M, Lischnig U, Lueger A, Stark G, Pilger E. The effect
of the K+ agonist nicorandil on peripheral vascular resistance. Int J
Cardiol. 2006;111:49–52.
111. Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T,
et al. Vasodilatory effect of nicorandil on coronary arterial
microvessels: its dependency on vessel size and the involvement
of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol.
1995;26:541–7.
112. Aizawa T, Ogasawara K, Kato K. Effects of nicorandil on coro-
nary circulation in patients with ischemic heart disease: compari-
son with nitroglycerin. J Cardiovasc Pharmacol. 1987;10(Suppl
8):S123–9.
113. Treese N, Erbel R, Meyer J. Acute hemodynamic effects of
nicorandil in coronary artery disease. J Cardiovasc Pharmacol.
1992;20:S52.
114. Knight DC, Purcell H, Fox K. Potassium channel openers: clinical
applications in ischemic heart disease—overview of clinical effi-
cacy of nicorandil. Cardiovasc Drugs Ther Kluwer Acad
Publishers; 1995;9:229–236.
115. Suryapranata H, Serruys PW, de Feyter PJ. Coronary vasodilatory
action after a single dose of nicorandil. Am J Cardiol. 1988;61:
292–7.
116. Suryapranata H, MacLeod D. Nicorandil and cardiovascular per-
formance in patients with coronary artery disease. J Cardiovasc
Pharmacol. 1992;20(Suppl 3):S45–51.
117. Coltart DJ, Signy M. Acute hemodynamic effects of single-
dose nicorandil in coronary artery disease. Am J Cardiol.
1989;63:J34–9.
118. Markham A, Plosker GL, Goa KL. Nicorandil. An updated
review of its use in ischaemic heart disease with emphasis
on its cardioprotective effects. Drugs. Springer Int Publ.
2000;60:955–74.
119. Matsubara T, Minatoguchi S, Matsuo H, Hayakawa K, Segawa T,
Matsuno Y, et al. Three minute, but not one minute, ischemia and
nicorandil have a preconditioning effect in patients with coronary
artery disease. J Am Coll Cardiol. 2000;35:345–51.
120. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K.
Effects of the long-term administration of nicorandil on vascular
endothelial function and the progression of arteriosclerosis. J
Cardiovasc Pharmacol. 2005;46:63–7.
121. Serizawa K-I, Yogo K, Aizawa K, Tashiro Y, Ishizuka N.
Nicorandil prevents endothelial dysfunction due to antioxi-
dative effects via normalisation of NADPH oxidase and nitric
oxide synthase in streptozotocin diabetic rats. Cardiovasc
Diabetol. BioMed Central Ltd; 2011;10:105.
122. Serizawa K-I, Yogo K, Aizawa K, Tashiro Y, Takahari Y, Sekine
K, et al. Paclitaxel-induced endothelial dysfunction in living rats is
prevented by nicorandil via reduction of oxidative stress. J
Pharmacol Sci. 2012;119:349–58.
123. Ishibashi Y, Takahashi N, Tokumaru A, Karino K, Sugamori T,
Sakane T, et al. Effects of long-term nicorandil administration on
endothelial function, inflammation, and oxidative stress in patients
without coronary artery disease. J Cardiovasc Pharmacol.
2008;51:311–6.
124. Izumiya Y, Kojima S, Kojima S, Araki S, Usuku H, Matsubara J,
et al. Atherosclerosis. Atherosclerosis Elsevier Ireland Ltd.
2011;214:415–21.
125. Cavero I, Djellas Y, Guillon JM. Ischemic myocardial cell protec-
tion conferred by the opening of ATP-sensitive potassium chan-
nels. Cardiovasc Drugs Ther. 1995;9(Suppl 2):245–55.
126. Falase B, Easaw J, Youhana A. The role of nicorandil in the treat-
ment of myocardial ischaemia. Expert Opin Pharmacother.
2001;2:845–56.
127. Sato T, Sasaki N, O'Rourke B, Marbán E. Nicorandil, a potent
cardioprotective agent, acts by opening mitochondrial ATP-
dependent potassium channels. JAC. 2000;35:514–8.
128. Szewczyk A,Marbán E. Mitochondria: a new target for K channel
openers? Trends Pharmacol Sci. 1999;20:157–61.
129. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting
mitochondrial permeability transition pore opening: a new para-
digm for myocardial preconditioning? Cardiovasc Res. 2002;55:
534–43.
130. Wu H, Ye M, Yang J, Ding J, Yang J, Dong W, et al. Nicorandil
protects the heart from ischemia/reperfusion injury by attenuating
endoplasmic reticulum response-induced apoptosis through PI3K/
Akt signaling pathway. Cell Physiol Biochem Karger Publishers.
2015;35:2320–32.
131. IONA Study Group. Effect of nicorandil on coronary events in
patients with stable angina: the impact of nicorandil in angina
(IONA) randomised trial. Lancet. 2002;359:1269–75.
132. IONA Study Group. Impact of nicorandil in angina: subgroup
analyses. Heart. 2004;90:1427–30.
133. Henderson RA, O'Flynn N, Guideline Development Group.
Management of stable angina: summary of NICE guidance.
Heart. BMJ Publ Group Ltd and Br Cardiovasc Soc; 2012. pp.
500–7.
134. Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S,
et al. Effects of nicorandil on cardiovascular events in patients with
coronary artery disease in the Japanese coronary artery disease
(JCAD) study. Circ J. 2010;74:503–9.
135. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the
K(ATP) channel in unstable angina. Is this a clinical manifestation
of myocardial preconditioning? Results of a randomized study
with nicorandil. CESAR 2 investigation. Clinical European stud-
ies in angina and revascularization. Eur Heart J. 1999;20:51–7.
136. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of
nicorandil. Cardiovasc Drugs Ther. 1990;4:1075–88.
137. Awata N, Azuma J, Sawamura A, Harada H, Hamaguchi T, Park
S, et al. Efficacy of nicorandil on exercise performance in patients
with stable effort angina: exercise echocardiography evaluation.
Current therapeutic research. Elsevier. 1989;45:621–32.
138. Hiasa Y, Hamai K, Wada T, Aihara T, Bando M, Nakai Y, et al.
Chronic effects of nicorandil on exercise tolerance in patients with
stable effort angina pectoris. Tokushima J Exp Med.
1989;36:65–70.
139. Kinoshita M, Nishikawa S, Sawamura M, Yamaguchi S,
Mitsunami K, Itoh M, et al. Comparative efficacy of high-dose
versus low-dose nicorandil therapy for chronic stable angina
pectoris. Am J Cardiol. 1986;58:733–8.
140. Hayata N, Araki H, NakamuraM. Effects of nicorandil on exercise
tolerance in patients with stable effort angina: a double-blind
study. Am Heart J. 1986;112:1245–50.
Cardiovasc Drugs Ther
141. Camm AJ, Maltz MB. A controlled single-dose study of the effi-
cacy, dose response and duration of action of nicorandil in angina
pectoris. Am J Cardiol Elsevier. 1989;63:J61–5.
142. Why HJ, Richardson PJ. A potassium channel opener as mono-
therapy in chronic stable angina pectoris: comparison with place-
bo. Eur Heart J. 1993;14 Suppl B:25–29.
143. Meany TB, Richardson P, Camm AJ, Coltart J, Griffith M, Maltz
MB, et al. Exercise capacity after single and twice-daily doses of
nicorandil in chronic stable angina pectoris. Am J Cardiol Elsevier.
1989;63:J66–70.
144. Hanai Y,MitaM, Hishinuma S, Shoji M. Systematic review on the
short-term efficacy and safety of nicorandil for stable angina
pectoris in comparison with those of β-blockers, nitrates and cal-
cium antagonists. Yakugaku Zasshi. 2010;130:1549–63.
145. Döring G. Antianginal and anti-ischemic efficacy of nicorandil in
comparison with isosorbide-5-mononitrate and isosorbide
dinitrate: results from two multicenter, double-blind, randomized
studies with stable coronary heart disease patients. J Cardiovasc
Pharmacol. 1992;20(Suppl 3):S74–81.
146. Lai C, Onnis E, Solinas R, Orani E, Lai G, Cadeddu M, et al. A
new anti-ischemic drug for the treatment of stable effort angina
pectoris: nicorandil. Comparison with placebo and isosorbide-5-
mononitrate. Cardiologia. 1991;36:703–11.
147. Ulvenstam G, Diderholm E, Frithz G, Gudbrandsson T, Hedbäck
B, Höglund C, et al. Antianginal and anti-ischemic efficacy of
nicorandil compared with nifedipine in patients with angina
pectoris and coronary heart disease: a double-blind, randomized,
multicenter study. J Cardiovasc Pharmacol. 1992;20(Suppl 3):
S67–73.
148. Guermonprez JL, Blin P, Peterlongo F. A double-blind compari-
son of the long-term efficacy of a potassium channel opener and a
calcium antagonist in stable angina pectoris. Eur Heart J. 1993;14
Suppl B:30–34.
149. Hughes LO, Rose EL, Lahiri A, Raftery EB. Comparison of
nicorandil and atenolol in stable angina pectoris. Am J Cardiol.
1990;66:679–82.
150. Meeter K, Kelder JC, Tijssen JG, Bucx JJ, Henneman JA, Kerker
JP, et al. Efficacy of nicorandil versus propranolol in mild stable
angina pectoris of effort: a long-term, double-blind, randomized
study. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S59–66.
151. Di Somma S, Liguori V, Petitto M, Carotenuto A, Bokor D, de
Divitiis O, et al. A double-blind comparison of nicorandil and
metoprolol in stable effort angina pectoris. Cardiovasc Drugs
Ther. 1993;7:119–23.
152. Ciampricotti R, Schotborgh CE, DeKamPJ, van Herwaarden RH.
A comparison of nicorandil with isosorbide mononitrate in elderly
patients with stable coronary heart disease: The SNAPE study. Am
Heart J. Mosby; 2000;139
153. The SWAN Study. Comparison of the antiischaemic and
antianginal effects of nicorandil and amlodipine in patients with
symptomatic stable angina pectoris: the SWAN study. J Clin
Basic Cardiol. 1999;2:213–7.
154. Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ,
Bouthier J, et al. Pharmacokinetics of nicorandil. Am J Cardiol.
1989;63:25J–33J.
155. Wagner G. Selected issues from an overview on nicorandil: toler-
ance, duration of action, and long-term efficacy. J Cardiovasc
Pharmacol. 1992;20:S86.
156. KoolMJ, Spek JJ, Struyker Boudier HA, HoeksAP, RenemanRS,
van Herwaarden RH, et al. Acute and subacute effects of
nicorandil and isosorbide dinitrate on vessel wall properties
of large arteries and hemodynamics in healthy volunteers.
Cardiovasc Drugs Ther Kluwer Acad Publishers. 1995;9:
331–7.
157. Roland E. Safety profile of an anti-anginal agent with potassium
channel opening activity: an overview. Eur Heart J. 1993;14 Suppl
B:48–52.
158. Witchitz S, Darmon JY. Nicorandil safety in the long-term treat-
ment of coronary heart disease. Cardiovasc Drugs Ther.
1995;9(Suppl 2):237–43.
159. Agbo-Godeau S, Joly P, Lauret P, Szpirglas R, Szpirglas H.
Association of major aphthous ulcers and nicorandil. Lancet.
1998;352:1598–9.
160. Watson A, Ozairi OA, Fraser A, LoudonM, O'Kelly T. Nicorandil
associated anal ulceration. Lancet. 2002;360:546–7.
161. Dunn N, Freemantle S, Pearce G, Wilton LV, Mann RD. Safety
profile of nicorandil–prescription-event monitoring (PEM) study.
Pharmacoepidemiol Drug Saf. 1999;8:197–205.
162. Reimann F, Ashcroft FM, Gribble FM. Structural basis for the
interference between nicorandil and sulfonylurea action.
Diabetes. 2001;50:2253–9.
163. Hill JA, Feldman RL, Pepine CJ, Conti, CR. Randomized double-
blind comparison of nifedipine and isosorbide dinitrate in patients
with coronary arterial spasm. Am J Cardiol. 1982;49(2):431–8.
164. Lablanche JM, Bauters C, Leroy F, Bertrand ME. Prevention of
coronary spasm by nicorandil: comparison with nifedipine. J
Cardiovasc Pharmacol. 1992;20(Suppl 3):S82–5.
165. Takahashi J, Nihei T, Takagi Y, Miyata S, Odaka Y, Tsunoda R,
et al. Prognostic impact of chronic nitrate therapy in patients with
vasospastic angina: multicentre registry study of the Japanese cor-
onary spasm association. Eur heart J. The Oxford University
Press. 2015;36:228–37.
166. Russo G, Di Franco A, Lamendola P, Tarzia P, Nerla R, Stazi A,
et al. Lack of effect of nitrates on exercise stress test results in
patients with microvascular angina. Cardiovasc Drugs Ther.
2013;27:229–34.
167. Kaski JC, Rosano GM, Collins P, Nihoyannopoulos P, Maseri A,
Poole-Wilson PA. Cardiac syndrome X: clinical characteristics
and left ventricular function. Long-term follow-up study. J Am
Coll Cardiol. 1995;25:807–14.
168. Kaski JC, Valenzuela Garcia LF. Therapeutic options for the man-
agement of patients with cardiac syndrome X. Eur Heart J.
2001;22:283–93.
169. YamabeH, Namura H, Yano T, Fujita H, Kim S, IwahashiM, et al.
Effect of nicorandil on abnormal coronary flow reserve assessed
by exercise 201Tl scintigraphy in patients with angina pectoris and
nearly normal coronary arteriograms. Cardiovasc Drugs Ther.
1995;9:755–61.
170. Sadamatsu K, Inoue S, Tashiro H. Coronary slow flow phenome-
non caused by contrast-induced microvascular spasm. Intern Med.
2007;46:1991–3.
171. Sadamatsu K, Tashiro H, Yoshida K, Shikada T, Iwamoto K,
Morishige K, et al. Acute effects of isosorbide dinitrate and
nicorandil on the coronary slow flow phenomenon. Am J
Cardiovasc Drugs. 2010;10:203–8.
172. Kiyooka T, Kobayashi Y, Ikari Y. A case of vasospastic angina in
which the ergonovine provocation test with intracoronary
isosorbide dinitrate and nicorandil was effective in the diagnosis
ofmicrovascular spasm. Cardiovasc Interv Ther. 2014;29(4):344–9.
Cardiovasc Drugs Ther
